Compare Cassava Sciences Inc (FLNA) vs SMX Security Matters plc (SMX) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

SMX trades at $4.21, up 7.95% today, but exhibits severe financial distress with no revenue, negative EBITDA of -$130.44M, and deeply negative ROE of -819.22% for 2025. The technical outlook is bearish based on moving averages, though oscillators like the RSI signal oversold conditions. Recent news highlights the company's focus on its Digital Material Passport platform for recycled plastics and material traceability, aiming to capitalize on circular economy trends.

The investment outlook is highly speculative. While the stock appears cheap on P/B (0.09) and EV/EBITDA (0.02) multiples, this reflects extreme financial losses and operational cash burn. Positive media coverage contrasts with the fundamental reality, creating significant risk. Upside depends entirely on the successful commercialization of its technology, which remains unproven given the current lack of revenue.